MedTrace Logo

Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects

NCT01036035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-12-30

No results posted yet for this study

Summary

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

Conditions

  • Incontinence

Interventions

DRUG

Tolterodine

Comparison of different dosages of drug

DRUG

Pilocarpine

Comparison of different dosages of drug

DRUG

THVD-201

Comparison of different dosages of drug

DRUG

THVD-201

Comparison of different dosages of drug

DRUG

placebo capsule

Comparison of different dosages of drug

Sponsors & Collaborators

  • TheraVida, Inc.

    lead INDUSTRY

Principal Investigators

  • Joanne Marjason · Queensland Institute for Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01036035 on ClinicalTrials.gov